Diagnosis and Management of Anaplastic Thyroid Cancer

Ashish V. Chintakuntlawar; Robert L. Foote; Jan L. Kasperbauer; Keith C. Bible

doi:10.1016/j.ecl.2018.10.010

Diagnosis and Management of Anaplastic Thyroid Cancer

Ashish V. Chintakuntlawar, Robert L. Foote, Jan L. Kasperbauer, Keith C. Bible

Research output: Contribution to journal › Review article › peer-review

29 Scopus citations

Abstract

Anaplastic thyroid cancer (ATC) is a devastating and usually incurable diagnosis. Clinical and pathologic diagnosis is best assessed at a tertiary center with concentrated ATC expertise. Expeditious multidisciplinary management is recommended for optimal patient outcomes. Based on multiinstitutional and population-based studies, multimodal therapy that includes chemoradiotherapy with surgery (when feasible) is the preferred initial treatment because it is associated with incrementally improved overall survival. In ATC that carries a BRAF V600E somatic mutation, combination therapy with BRAF and MEK inhibitors has shown promise but needs further study. Immunotherapeutic agents in neoadjuvant and metastatic settings are being investigated.

Original language	English (US)
Pages (from-to)	269-284
Number of pages	16
Journal	Endocrinology and Metabolism Clinics of North America
Volume	48
Issue number	1
DOIs	https://doi.org/10.1016/j.ecl.2018.10.010
State	Published - Mar 2019

Keywords

Anaplastic thyroid cancer
Chemoradiotherapy
Multimodality therapy
Systemic therapy

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1016/j.ecl.2018.10.010

Cite this

@article{fdcb183cd908418bbbdb0bb882431d0b,

title = "Diagnosis and Management of Anaplastic Thyroid Cancer",

abstract = "Anaplastic thyroid cancer (ATC) is a devastating and usually incurable diagnosis. Clinical and pathologic diagnosis is best assessed at a tertiary center with concentrated ATC expertise. Expeditious multidisciplinary management is recommended for optimal patient outcomes. Based on multiinstitutional and population-based studies, multimodal therapy that includes chemoradiotherapy with surgery (when feasible) is the preferred initial treatment because it is associated with incrementally improved overall survival. In ATC that carries a BRAF V600E somatic mutation, combination therapy with BRAF and MEK inhibitors has shown promise but needs further study. Immunotherapeutic agents in neoadjuvant and metastatic settings are being investigated.",

keywords = "Anaplastic thyroid cancer, Chemoradiotherapy, Multimodality therapy, Systemic therapy",

author = "Chintakuntlawar, {Ashish V.} and Foote, {Robert L.} and Kasperbauer, {Jan L.} and Bible, {Keith C.}",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2019",

month = mar,

doi = "10.1016/j.ecl.2018.10.010",

language = "English (US)",

volume = "48",

pages = "269--284",

journal = "Endocrinology and Metabolism Clinics of North America",

issn = "0889-8529",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Diagnosis and Management of Anaplastic Thyroid Cancer

AU - Chintakuntlawar, Ashish V.

AU - Foote, Robert L.

AU - Kasperbauer, Jan L.

AU - Bible, Keith C.

PY - 2019/3

Y1 - 2019/3

N2 - Anaplastic thyroid cancer (ATC) is a devastating and usually incurable diagnosis. Clinical and pathologic diagnosis is best assessed at a tertiary center with concentrated ATC expertise. Expeditious multidisciplinary management is recommended for optimal patient outcomes. Based on multiinstitutional and population-based studies, multimodal therapy that includes chemoradiotherapy with surgery (when feasible) is the preferred initial treatment because it is associated with incrementally improved overall survival. In ATC that carries a BRAF V600E somatic mutation, combination therapy with BRAF and MEK inhibitors has shown promise but needs further study. Immunotherapeutic agents in neoadjuvant and metastatic settings are being investigated.

AB - Anaplastic thyroid cancer (ATC) is a devastating and usually incurable diagnosis. Clinical and pathologic diagnosis is best assessed at a tertiary center with concentrated ATC expertise. Expeditious multidisciplinary management is recommended for optimal patient outcomes. Based on multiinstitutional and population-based studies, multimodal therapy that includes chemoradiotherapy with surgery (when feasible) is the preferred initial treatment because it is associated with incrementally improved overall survival. In ATC that carries a BRAF V600E somatic mutation, combination therapy with BRAF and MEK inhibitors has shown promise but needs further study. Immunotherapeutic agents in neoadjuvant and metastatic settings are being investigated.

KW - Anaplastic thyroid cancer

KW - Chemoradiotherapy

KW - Multimodality therapy

KW - Systemic therapy

UR - http://www.scopus.com/inward/record.url?scp=85060885342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060885342&partnerID=8YFLogxK

U2 - 10.1016/j.ecl.2018.10.010

DO - 10.1016/j.ecl.2018.10.010

M3 - Review article

C2 - 30717908

AN - SCOPUS:85060885342

SN - 0889-8529

VL - 48

SP - 269

EP - 284

JO - Endocrinology and Metabolism Clinics of North America

JF - Endocrinology and Metabolism Clinics of North America

IS - 1

ER -

Diagnosis and Management of Anaplastic Thyroid Cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this